Study details
Enrolling now
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT IDNCT07493538ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
2–75
Locations
1 site in MN
What this study is about
This Phase 2 study is testing Cyclophosphamid in people with acute leukemia. The primary outcome being measured is Overall Survival.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), tacrolimus, treosulfan
Drug routes
injection, intravenous, infusion, injection (Injection)
Endpoints
Primary: Overall Survival
Secondary: Overall Survival
Procedures
radiation
Body systems
Oncology